Skip to content
Screener

Zymeworks ZYME Deferred Tax Assets

Deferred Tax Assets at other companies

Pfizer logo
PfizerPFE
-$12M-101%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$4.94M+32.6%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$21.65M-32.8%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
AssetsJune 30,2026 / (unaudited)December 31,2025
Deferred revenue14,606
Liability related to sale of future royalties252,631
Other long-term liabilities278278
Deferred tax liability3,7406,028
Total liabilities316,59578,026
Stockholders’ equity:
Common stock, $0.00001 par value; 900,000,000 authorized shares at June 30, 2026 and December 31, 2025, respectively; 71,412,072 and 74,638,413 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1,133,9591,105,176
Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of June 30, 2026 and December 31, 2025

Item 1. Financial Statements

FAQ

What is Zymeworks's deferred tax assets?
Zymeworks (ZYME) reported deferred tax assets of $3.74M in Q2 2026.
How has Zymeworks's deferred tax assets changed year-over-year?
Zymeworks's deferred tax assets decreased by 22.9% year-over-year, from $4.85M to $3.74M.
What is the long-term trend for Zymeworks's deferred tax assets?
Over 2 years (2023 to 2025), Zymeworks's deferred tax assets has grown at a 50.5% compound annual growth rate (CAGR), from $9.04M to $20.47M.
What does deferred tax assets mean?
Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.

Ask your AI about Zymeworks's deferred tax assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude